Metabolism of roxithromycin in the isolated perfused rat liver

被引:6
作者
Jarukamjorn, K
Thalhammer, T
Gollackner, B
Pittenauer, E
Jäger, W
机构
[1] Univ Vienna, Inst Pharmaceut Chem, A-1090 Vienna, Austria
[2] Univ Vienna, Dept Gen & Expt Pathol, A-1090 Vienna, Austria
[3] Univ Vienna, Dept Surg, A-1090 Vienna, Austria
[4] Fed Off & Res Ctr Agr, Inst Agr Ecol, Vienna, Austria
关键词
D O I
10.1111/j.2042-7158.1998.tb06193.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Roxithromycin is a macrolide antibiotic with high clinical potency. N-Demethylation is considered to be one of the main pathways of roxithromycin metabolism in rats. We have studied the hepatic metabolism of roxithromycin in the isolated perfused rat liver. After addition of roxithromycin (30 mu M) to the perfusion medium the parent compound and one major metabolite were detected in bile by high-performance liquid chromatography. The metabolite was identified as monodesmethylated roxithromycin by mass spectrometric analysis. Onset of biliary excretion of native roxithromycin was fast, reaching a maximum (130.52 +/- 43.88 pmolg(-1)min(-1)) after only 10min, whereas excretion of the metabolite was delayed (maximum 75.83 +/- 11.92 pmolg(-1)min(-1) at 30min). The cumulative excretion of roxithromycin and its metabolite into bile during the 60min of application amounted to only 1.09 +/- 0.30 and 0.64 +/- 0.22% of the roxithromycin cleared from the perfusate during the same time. The liver content was 0.48 mu mol (gliver)(-1) indicating high retention within the organ. No release of the metabolite into the perfusate was detected. In conclusion, this study has demonstrated the importance of phase-I metabolism for the biliary excretion of roxithromycin in rat liver. These findings might be predictive of roxithromycin biotransformation and biliary excretion in man.
引用
收藏
页码:515 / 519
页数:5
相关论文
共 15 条
[1]   SINGLE ORAL DOSE PHARMACOKINETICS OF ERYTHROMYCIN AND ROXITHROMYCIN AND THE EFFECTS OF CHRONIC DOSING [J].
BIRKETT, DJ ;
ROBSON, RA ;
GRGURINOVICH, N ;
TONKIN, A .
THERAPEUTIC DRUG MONITORING, 1990, 12 (01) :65-71
[2]   INVOLVEMENT OF CYP2D6, CYP3A4, AND OTHER CYTOCHROME-P-450 ISOZYMES IN N-DEALKYLATION REACTIONS [J].
COUTTS, RT ;
SU, P ;
BAKER, GB .
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 1994, 31 (04) :177-186
[3]   INVIVO AND INVITRO EFFECTS OF A NEW MACROLIDE ANTIBIOTIC ROXITHROMYCIN ON RAT-LIVER CYTOCHROME-P-450 - COMPARISON WITH TROLEANDOMYCIN AND ERYTHROMYCIN [J].
DELAFORGE, M ;
SARTORI, E ;
MANSUY, D .
CHEMICO-BIOLOGICAL INTERACTIONS, 1988, 68 (3-4) :179-188
[4]  
DURANT J, 1994, INFECTION S1, V23, pS33
[5]  
GUENGERICH FP, 1995, ADV DRUG METABOLISM, P181
[6]  
HANSEN K, 1992, ACTA DERM-VENEREOL, V2, P348
[7]   EVIDENCE FOR THE ESSENTIAL ROLE OF HELICOBACTER-PYLORI IN GASTRIC-ULCER DISEASE [J].
LABENZ, J ;
BORSCH, G .
GUT, 1994, 35 (01) :19-22
[8]   EFFECTS OF ERYTHROMYCIN ON HEPATIC DRUG-METABOLIZING-ENZYMES IN HUMANS [J].
LARREY, D ;
FUNCKBRENTANO, C ;
BREIL, P ;
VITAUX, J ;
THEODORE, C ;
BABANY, G ;
PESSAYRE, D .
BIOCHEMICAL PHARMACOLOGY, 1983, 32 (06) :1063-1068
[9]   ROXITHROMYCIN - AN UPDATE OF ITS ANTIMICROBIAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC USE [J].
MARKHAM, A ;
FAULDS, D .
DRUGS, 1994, 48 (02) :297-326
[10]  
MCLEAN A, 1987, BR J CLIN PRACT, V55, P52